In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Citius Pharmaceuticals Inc (NASDAQ: CTXR) was $1.24 for the day, down -9.49% from the previous closing price of $1.37. In other words, the price has decreased by -$9.49 from its previous closing price. On the day, 0.51 million shares were traded. CTXR stock price reached its highest trading level at $1.37 during the session, while it also had its lowest trading level at $1.225.
Ratios:
Our analysis of CTXR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.14 and its Current Ratio is at 0.47. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
On November 30, 2021, Maxim Group started tracking the stock assigning a Buy rating and target price of $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTXR now has a Market Capitalization of 22905518 and an Enterprise Value of 19390022.
Stock Price History:
The Beta on a monthly basis for CTXR is 1.52, which has changed by -0.8669903 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, CTXR has reached a high of $12.84, while it has fallen to a 52-week low of $0.65. The 50-Day Moving Average of the stock is -7.70%, while the 200-Day Moving Average is calculated to be -12.10%.
Shares Statistics:
CTXR traded an average of 739.29K shares per day over the past three months and 471480 shares per day over the past ten days. A total of 18.47M shares are outstanding, with a floating share count of 17.98M. Insiders hold about 2.67% of the company’s shares, while institutions hold 11.98% stake in the company. Shares short for CTXR as of 1760486400 were 1581959 with a Short Ratio of 2.14, compared to 1757894400 on 1033868. Therefore, it implies a Short% of Shares Outstanding of 1581959 and a Short% of Float of 9.58.
Earnings Estimates
The market rating for Citius Pharmaceuticals Inc (CTXR) is a result of the insights provided by 1.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.3, with high estimates of -$0.3 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$2.08 and -$2.08 for the fiscal current year, implying an average EPS of -$2.08. EPS for the following year is $1.9, with 1.0 analysts recommending between $1.9 and $1.9.
Revenue Estimates
For the next quarter, 2 analysts are estimating revenue of $3.46M. There is a high estimate of $3.46M for the next quarter, whereas the lowest estimate is $3.46M.
Based on 2 analysts’ estimates, the company’s revenue will be $63.82M in the next fiscal year. The high estimate is $78.29M and the low estimate is $49.35M.
